FIGURE 1: Poly(A:U) 50 bp TL-412 increases mTNFα secretion by RAW264.7 wt cells, while Poly(A:U) 70 bp TL-432 and 90 bp TL-452 trigger biological responses in both RAW264.7 wt and NCI-H292 wt cells. (A, D) Activation of myeloid cells by TLR3-ligands was determined on RAW264.7 cells treated with the different molecules at 10 µg/mL for 24 hours. The concentration of mTNFα was measured by ELISA. (B, E, F) Activation of tumor cells by TLR3-ligands was determined on NCI-H292 cells treated with the different molecules at 50 µg/mL for 24 hours. Cell viability was measured with MTS assay and expressed as percentage of untreated cells (B, F). Apoptosis was measured with AnnexinV-Glo assay and expressed as fold increase of untreated cells (E). (A) Among 47 tested 50 bp dsRNAs, only the Poly(A:U) (TL-412) induces mTNFα secretion by RAW264.7 wt cells. (B) None of the tested 50 bp dsRNAs reduces cell viability in NCI-H292 wt. (C) Schematic representation of a subset of dsRNA ligands, showing their sizes and compositions. TL-413, made of a random sequence containing A-U nucleotides, is represented in square. (D) Increasing the size of Poly(A:U) from 50 to 70 or 90 bp does not increase mTNFα secretion by RAW264.7 wt cells. (E, F) Increasing the size of Poly(A:U) from 50 to 70 or 90 bp triggers apoptosis and reduces cell viability in NCI-H292 wt. Data are representative of one (B) or at least two (A) independent assays or are the means of three independent assays (D-F). Results are expressed as mean ± SD. Unpaired Student's t-test: * = p<0.05; ** = p<0.01; *** = p<0.001; ns: not significant. Unpaired Student's t-test values are compared to Mock condition unless otherwise stated.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.

Close